Navigation Links
PharmAthene Files Registration Statement On Form S-4 With The Securities and Exchange Commission
Date:9/9/2013

r elimination of U.S. government funding for one or more of the combined company's development programs; the award of government contracts to competitors; unforeseen safety issues; unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products; as well as risks detailed from time to time in PharmAthene's Form 10-K and quarterly reports on Form 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, there is significant uncertainty regarding the level and timing of sales of Arestvyr™ and when and whether it will be approved by the U.S. FDA and corresponding health agencies around the world. PharmAthene cannot predict with certainty if or when SIGA will begin recognizing profit on the sale thereof and there can be no assurance that any profits received by SIGA will be significant. In its May 2013 decision, the Delaware Supreme Court reversed the remedy ordered by the Court of Chancery and remanded the issue of a remedy back to the trial court for reconsideration in light of the Supreme Court's opinion.  As a result, there can be no assurance that the Chancery Court will issue a remedy that provides PharmAthene with a financial interest in Arestvyr™ and related products or any remedy.  In addition, significant additional research work, non-clinical animal studies, clinical trials, and manufacturing development work remain to be done with respect to all of PharmAthene's product candidates. At this point there can be no assurance that any of these product candidates will be shown to be safe and effective and approved by regulatory authorities for use in humans.   Copies of PharmAthene's public disclosure filings are available from its investor relations department and its website under the investor relations tab at http://www.pharmathene.com.
'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
3. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
4. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
5. PharmAthene Reports First Quarter 2012 Financial Results
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
8. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
9. PharmAthene Reports Year-End 2012 Financial And Operational Results
10. PharmAthene To Host First Quarter 2013 Conference Call And Webcast On Wednesday, May 8, 2013
11. PharmAthene to Host Second Quarter 2013 Conference Call and Webcast on Wednesday, August 7, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 Richmond Pharmacology ... Richmond Pharmacology ist das erste Zentrum weltweit, das ... Free Hospital in London ... RNAi-Therapeutikums Studienversuche an einem Patienten begonnen hat. Das ... Amyloidose entwickelt (ATTR), einer seltenen Herz- und Nervenkrankheit. ...
(Date:3/29/2015)... 2015  Caris Life Sciences® today announced ... cell cervical cancer (SCCC) that shows multiplatform ... company,s panomic, comprehensive tumor profiling service, identified high ... explain sensitivities and resistance to common drug ... biomarkers may guide treatment strategies in rare, ...
(Date:3/27/2015)... Earlier this year, the Capillus272Pro™ ... regrowth in adult men and women with androgenic alopecia ... classifications of IIa-V and Fitzpatrick Classification of Skin phototypes ... that over-promise and under-deliver, FDA Clearance underscores the safety ... among more than 80 million men and women who ...
(Date:3/27/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today that ... in accordance with Securities and Exchange Commission rule 10b5-1. ... Corporation, is a minority owner of this entity that ... Herbert does not have control of this entity, but ... for a portion of the shares owned by that ...
Breaking Biology Technology:Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2Neogen CEO adopts 10b5-1 Trading Plan 2
... isn,t a very powerful force, but it matters for small ... Nanowires are so tiny that a human hair would ... meter. Because of their small size, surface tension that occurs ... This is a problem because the wires are seen as ...
... July 21 The Lucian Leape Institute at ... discussion and special evening program at its Third Annual ... .  David Blumenthal, M.D., M.P.P., will deliver a keynote address ... as a patient safety lever and the focus placed on ...
... N.C. , July 21 Chimerix, Inc., a biotechnology ... its clinical management team with the appointment of Timothy King ... MD, as Vice President of Clinical Research.   , ... In these new roles, Mr. ...
Cached Biology Technology:Engineering researchers simplify process to make world's tiniest wires 2David Blumenthal, HHS National Coordinator for Health Information Technology, to Speak at Lucian Leape Institute Third Annual Forum & Gala on Sept. 16 2David Blumenthal, HHS National Coordinator for Health Information Technology, to Speak at Lucian Leape Institute Third Annual Forum & Gala on Sept. 16 3David Blumenthal, HHS National Coordinator for Health Information Technology, to Speak at Lucian Leape Institute Third Annual Forum & Gala on Sept. 16 4Chimerix Appoints Two New Vice Presidents to Clinical Management Team 2Chimerix Appoints Two New Vice Presidents to Clinical Management Team 3
(Date:3/26/2015)... 26, 2015 The Granite Club, ... and athletic club, today announced it has implemented a ... of movement for members and staff, while restricting access ... process, we selected FST,s IMID Access system because it ... our members and staff, in addition to unparalleled security," ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ... solutions, today announced that its U.are.U ® ... retailer Goorin Bros . to achieve PCI ... solution secures access to the POS terminal, protecting ... risk of data breaches. With ...
(Date:3/23/2015)... Conn. , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... new advertising campaign on CNBC television starting March 30 th ... will commence airing in New York ... Officer said: "We are excited about our new ad campaign ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... EMBO today announces the selection of seven scientists as ... will assist the researchers to relocate and set up ... "The EMBO Installation Grants directly support young scientists ... Wallon, Installation Grants Programme Manager and EMBO Deputy Director. ...
... bioprocessing engineers with Kansas State University,s Advanced Manufacturing Institute ... removes phosphorus from wastewater and addresses environmental regulations. ... an important environmental problem. It can pollute water resources ... in many Kansas lakes and reservoirs this summer. ...
... This press release is available in German ... Foundation) will establish eight Collaborative Research Centres (CRC) as of ... Committee at its autumn meeting in Bonn. The new CRCs ... 20 percent programme allowance for indirect project costs) in their ...
Cached Biology News:Benefits abound with recently patented system that reduces phosphorus in wastewater 2Benefits abound with recently patented system that reduces phosphorus in wastewater 3DFG to fund 8 new collaborative research centers 2DFG to fund 8 new collaborative research centers 3DFG to fund 8 new collaborative research centers 4DFG to fund 8 new collaborative research centers 5
Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Human CXCL14/BRAK Affinity Purified Polyclonal Ab...
mIGSF4A Aff Pur PAb...
Biology Products: